Onset and Duration of the Effects of Three Antihistamines in Current Use – Astemizole, Loratadine and Terfenadine Forte – Studied during Prolonged, Controlled Allergen Challenges in Volunteers
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In a three-way, double-blind, crossover study the onset of action and effects at the end of the dosing interval of 10 mg/day astemizole, 10 mg/day loratadine and 120 mg/day terfenadine forte given for 3 days to six atopic volunteers were assessed using the Vienna challenge chamber (VCC). With each treatment, two long-term pollen challenges were performed in the VCC: the first to assess the onset of action started 1 h before the first dose and lasted continuously for 5 h; the second to assess the effects at the end of dosing took place 21 h after the last of the three doses and lasted 3 h. All three drug treatments initiated 1 h after the beginning of challenge with grass pollen reversed the adverse effects of challenge on the subjective symptoms (runny, blocked or itchy nose, sneezing, itchy eyes, tears) and the objective parameters (nasal secretions, nasal resistance, nasal flow, flow increase, nasal peak flow) within 1 − 3 h. The mean time to onset of action was 107 min for astemizole, 117 min after treatment for loratadine and 153 min for terfenadine forte. During the second allergen challenge, 21 − 24 h after intake, astemizole consistently provided better protection for all parameters than did loratadine or terfenadine forte; however the differences were not statistically significant. In einer doppelblinden Dreiwege-Crossover-Studie wurden der Wirkungsbeginn und die Effekte am Ende des Dosierungsintervalls von 10 mg/Tag Astemizol, 10 mg/Tag Loratadin und 120 mg/Tag Terfenadin forte beurteilt. Die drei Medikamente wurden für die Dauer von 3 Tagen an sechs allergische Freiwillige verabreicht. Für die Beurteilung wurde die “Wiener Provokations-Kammer” benutzt. Mit jeder Behandlung wurden zwei langzeitige Pollenexpositionen in der Wiener-Kammer durchgeführt. Die erste Exposition, die 1 h vor Verabreichung der ersten Dosis begonnen wurde, diente der Abklärung des Wirkungsbeginns und wurde ununterbrochen über 5 h fortgeführt, wohingegen die zweite zur Abklärung der Effekte am Ende der Dosierung, 21 h nach der letzten der drei Dosen vorgenommen wurde und 3 h dauerte. Mit alien drei medikamentösen Behandlungen, die 1 h nach Beginn der Provokation mit Graspollen eingeleitet wurden, konnten die klinisch erfaßbaren Wirkungen der Provokation auf die subjektiven Symptome (laufende, verstopfte oder juckende Nase, Nießreiz, juckende Augen, tränende Augen) aufgehoben werden. Die objektiven Parameter (Sekretproduktion der Nase, Nasenwiderstand, Nasendurchfluß, Durchflußzunahme, Nasen-Peakflow) zeigten nach 1 − 3 h eine Verbesserung. Die mittlere Zeit bis zum Wirkungsbeginn betrug für Astemizol 107 min, für Loratadin 117 min nach der Behandlung und für Terfenadin forte 153 min. Während der zweiten Allergenexposition, 21–24 h nach der Einnahme, stellte Astemizol für alle Parameter gleichbleibend einen besseren Schutz bereit als Loratadin oder Terfenadin forte. Die Unterschiede waren jedoch nicht statistisch signifikant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reinberg, A., Gervais, P., Levi, F., Smolensky, M., Del Cerro, L., & Ugolini, C. (1988) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(88)90220-5 · Cited by 115
Cited by
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Bousquet, J., Schünemann, H. J., Togias, A., Bachert, C., Erhola, M., Hellings, P. W., Klimek, L., Pfaar, O., Wallace, D., Ansotegui, I., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.049 · Cited by 609
Krug, N., Loedding, H., Hohlfeld, J. M., Larbig, M., Buckendahl, A., Badorrek, P., Geldmacher, H., Behnke, W., Dunkhorst, W., Windt, H., et al. (2003) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2003.01810.x · Cited by 73
Zieglmayer, P., Zieglmayer, R., Bareille, P., Rousell, V., Salmon, E., & Horak, F. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802155792 · Cited by 35
Self-citationRønborg, S. M., Mosbech, H., & Poulsen, L. K. (1997) · Allergy · doi:10.1111/j.1398-9995.1997.tb02153.x · Cited by 21
Metadata
- Authors
- Horak, F., Jäcer, S., & Berger, U.
- Venue
- Journal of International Medical Research
- Publisher
- SAGE Publications
- Published
- 1992-09
- Volume
- 20
- Issue
- 5
- Pages
- 422-434
- ISSN
- 0300-0605 (ISSN-L)
- 1473-2300
- OpenAlex
- W2287611346
- Cited by
- 27
- References
- 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.